Last updated on: 19 February 2025
In 2002, as HIV/AIDS and other infectious diseases wreaked havoc, world leaders—including the European Commission—united to establish the Global Fund. Their aim was to ensure access to life-saving treatment for those affected by HIV, tuberculosis, and malaria. Since then, the Global Fund has saved 65 million lives and reduced death rates from these diseases by 63%. While significant progress has been made, HIV, TB, and malaria continue to claim millions of lives each year. Climate change, conflict, cuts to official development assistance (ODA), and shifting global priorities threaten to stall or even reverse these gains. If we stop progressing, the diseases start progressing.
Yesterday, the Global Fund launched a new Investment Case, aiming to raise US$18 billion to prevent 400 million new infections and save 23 million lives by 2029. Ensuring the Global Fund is fully funded is critical – not only to preserve past achievements but also to secure a healthier, disease-free future for all.
On the occasion of the release of the Investment Case, we – together with Friends of the Global Fund – are publishing a report highlighting the unique nature of the European Commission’s partnership with the Global Fund. The EC played a key role in the creation and development of the Global Fund and has been instrumental in its success to date.
In the face of today’s immense challenges, Aidsfonds and Friends of the Global Fund Europe urge the European Commission to rise to the occasion. The goal of ending HIV, TB, and malaria by 2030 remains within reach, but sustained investment is essential to achieving it.
Read our report
Photo credits: The Global Fund/Tim Knox
